Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Relationship between myeloma cell genomic alternations and tumor immune microenvironment in bone-related extramedullary disease of newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YXYang Xu

Discussion

Loading...

Member takes

Overview

Analysis reveals TP53 mutations relate to immune profile disruption and reduced regulatory T cells in multiple myeloma.

Key Points

  • Investigate how genomic alterations in myeloma cells impact the tumor immune microenvironment in newly diagnosed multiple myeloma.
  • Collected fresh tissue samples from 28 MM patients with bone-related lesions.
  • Conducted DNA extraction and targeted DNA sequencing on samples.
  • Performed immune microenvironment analysis using CyTOF and single-cell RNA sequencing.
  • Performed fluorescence in situ hybridization to analyze specific mutations and abnormalities.
  • Identified relationships between TP53 abnormalities and decreased effector T cells and increased regulatory T cells.
  • Reduced NK cell proportions linked to 1q21 amplification and 17p deletion.
  • Single-cell sequencing showed heightened expression of inhibitory molecules in TP53-abnormal microenvironments.

Cite This Study

Yang Xu (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6d4https://doi.org/10.1182/blood-2025-5722
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-omics profiling reveals an immunosuppressive microenvironment and PRL-3 as a therapeutic target in myeloma extramedullary disease2025
  2. 2Abstract 1223: Spatial transcriptomics identifies a suppressive T-cell excluded tumour microenvironment in extramedullary multiple myeloma.2026
  3. 3Spatially resolved transcriptomics reveals immunosuppressive niches and clonal diversity in extramedullary disease in multiple myeloma refractory to immunotherapy2025
  4. 4Genomic and transcriptomic signatures of extramedullary multiple myeloma reveal possible drivers of therapeutic resistance2025
  5. 5Composition and functional state of T and NK cells in the extramedullary myeloma tumor microenvironment2025